Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O) agent in Phase III development for the treatment of lung cancer, invites investors and the general public to listen to a webcast of its roundtable discussion in conjunction with the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. This roundtable is comprised of key opinion leaders in the field of Immunotherapy who will discuss novel I-O combination therapies that may improve patient outcomes.

Title: “Raising the Immuno-Oncology Bar: The Next Wave of Immune Modulating Checkpoint Inhibitors”
Date/ Time: Sunday, May 31, 2015 from 6:00- 7:00 PM Central Time

The event is being hosted by Peregrine Pharmaceuticals and will be webcast live and archived for 60 days. The event may be accessed from the home page of Peregrine Pharmaceuticals’ website at For the live event, listeners are encouraged to login 5 to 10 minutes ahead of the scheduled start in order to verify system requirements and complete registration.

Lori Kunkel, M.D. will moderate this event. Dr. Kunkel serves on the Board of Directors of Loxo Oncology, where she held the position of Acting Chief Medical Officer. Previously, Dr. Kunkel was Chief Medical Officer at Pharmacyclics and Proteolix and has also held senior roles at ACT Therapeutics, Syndax, Xencor, and Genitope. Dr. Kunkel received her M.D. from the University of Southern California and her B.A. degree from the University of California San Diego.

The panel includes:

  • Scott J. Antonia, M.D., Ph.D., Department Chair, Program Leader, Thoracic Oncology Department Associate Professor Department of Interdisciplinary Oncology and Program Leader of the Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  • Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor in Cancer Research, and Program Leader, Translational Tumor Immunology, The Wistar Institute, Philadelphia, Pennsylvania
  • Kathy D. Miller, M.D., Ballve Lantero Scholar in Oncology, Professor, Department of Medicine, Co-Director, Simon Cancer Center Breast Cancer Program, Indiana University School of Medicine, Indianapolis, Indiana
  • Dmitriy Zamarin, M.D., Ph.D., Assistant Attending Physician, Gynecologic Medical Oncology and Immunotherapeutics, Memorial Sloan Kettering Cancer Center, New York, New York
  • Matthew D. Hellman, M.D., Assistant Attending Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York
  • Alexander M. Lesokhin, M.D., Assistant Member, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center, New York, New York
  • Rolf A. Brekken, Ph.D., Effie Marie Cain Research Scholar in Angiogenesis Research, Professor, Departments of Surgery and Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas (Original Source)

Shares of Peregrine Pharma closed today at $1.31, up $0.01 or 0.77%. PPHM has a 1-year high of $2 and a 1-year low of $1.19. The stock’s 50-day moving average is $1.36 and its 200-day moving average is $1.38.

On the ratings front, Peregrine has been the subject of a number of recent research reports. In a report issued on April 20, Roth Capital analyst Joseph Pantginis maintained a Buy rating on PPHM, with a price target of $5, which implies an upside of 282% from current levels. Separately, on March 13, MLV & Co.’s Thomas Yip reiterated a Buy rating on the stock and has a price target of $3.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Thomas Yip have a total average return of 7.0% and 0.5% respectively. Pantginis has a success rate of 48.9% and is ranked #394 out of 3607 analysts, while Yip has a success rate of 18.2% and is ranked #2522.

Peregrine Pharmaceuticals Inc is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for treatment & diagnosis of cancer. With its phosphatidylserine-targeting platform, it is pursuing two clinical programs in cancer.